Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell th...

Descripción completa

Detalles Bibliográficos
Autores principales: Walti, Carla S., Krantz, Elizabeth M., Maalouf, Joyce, Boonyaratanakornkit, Jim, Keane-Candib, Jacob, Joncas-Schronce, Laurel, Stevens-Ayers, Terry, Dasgupta, Sayan, Taylor, Justin J., Hirayama, Alexandre V., Bar, Merav, Gardner, Rebecca A., Cowan, Andrew J., Green, Damian J., Boeckh, Michael J., Maloney, David G., Turtle, Cameron J., Hill, Joshua A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262349/
https://www.ncbi.nlm.nih.gov/pubmed/33914708
http://dx.doi.org/10.1172/jci.insight.146743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262349/
https://www.ncbi.nlm.nih.gov/pubmed/33914708
http://dx.doi.org/10.1172/jci.insight.146743

Ejemplares similares